
Kura Oncology, Inc. (NASDAQ:KURA – Free Report) – Research analysts at Brookline Capital Markets cut their FY2029 earnings per share (EPS) estimates for shares of Kura Oncology in a research report issued to clients and investors on Tuesday, November 10th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $5.59 per share for the year, down from their prior estimate of $5.70. The consensus estimate for Kura Oncology’s current full-year earnings is ($3.21) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s FY2030 earnings at $17.45 EPS.
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. The business had revenue of $22.84 million for the quarter, compared to analysts’ expectations of $24.94 million.
Read Our Latest Stock Report on Kura Oncology
Kura Oncology Stock Up 4.6%
NASDAQ:KURA opened at $7.77 on Thursday. Kura Oncology has a one year low of $6.75 and a one year high of $13.90. The firm’s fifty day moving average price is $10.17 and its two-hundred day moving average price is $9.77. The company has a current ratio of 3.60, a quick ratio of 4.71 and a debt-to-equity ratio of 0.07.
Insider Transactions at Kura Oncology
In other Kura Oncology news, insider Brian Powl sold 17,020 shares of the company’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $10.53, for a total value of $179,220.60. Following the transaction, the insider directly owned 152,249 shares of the company’s stock, valued at $1,603,181.97. This represents a 10.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Francis Burrows sold 20,726 shares of the stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $10.83, for a total value of $224,462.58. Following the transaction, the insider owned 42,327 shares in the company, valued at $458,401.41. The trade was a 32.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 153,881 shares of company stock worth $1,708,183. 7.60% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Kura Oncology
Institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc raised its stake in Kura Oncology by 136.5% in the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after purchasing an additional 1,467 shares in the last quarter. Sterling Capital Management LLC grew its position in shares of Kura Oncology by 842.5% during the 3rd quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock worth $30,000 after purchasing an additional 2,519 shares in the last quarter. Physician Wealth Advisors Inc. acquired a new position in shares of Kura Oncology during the 3rd quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kura Oncology during the 3rd quarter worth approximately $49,000. Finally, Allworth Financial LP bought a new position in shares of Kura Oncology during the second quarter worth approximately $113,000.
Trending Headlines about Kura Oncology
These are some of the KURA headlines that stood out recently:
- Positive Sentiment: HC Wainwright raised its EPS forecasts for 2026–2029, reflecting less-negative projected losses. Brookline also lifted its 2026–2028 estimates, though its Q4 revision was downward. Analyst estimates
- Neutral Sentiment: Kura said management will participate in two November investor conferences. The events may provide a forum for updates, but no new corporate or clinical news was disclosed in the announcement. Article: Kura Oncology to Participate in Two Investor Conferences in November
- Negative Sentiment: Brookline lowered its Q4 2026 EPS estimate, projecting a loss of $0.97 per share versus its prior $0.89 loss estimate—a cautionary counterpoint to the broader estimate increases. Analyst estimates
Kura Oncology Company Profile
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Read More
- Five stocks we like better than Kura Oncology
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
